Identification of stromal proteins overexpressed in nodular sclerosis Hodgkin lymphoma

Proteome Science

Vincent Castronovo³  Laurence de Leval²  Edwin De Pauw¹  Gabriel Mazzucchelli¹  Yannick Greffe³  David Waltregny³  Philippe Kischel³ 

[1] Laboratory of Mass Spectrometry, Department of Chemistry, University of Liege, Bat. B6c, B-4000 Liège, Belgium;Department of Pathology, University Hospital of Liege, Bat. B23, CHU Sart Tilman Liège, B-4000 Liege, Belgium;Metastasis Research Laboratory, GIGA Cancer, University of Liege, Bat. B23, CHU Sart Tilman Liège, B-4000 Liège, Belgium

关键词: Tumour targeting;    Mass spectrometry;    Lymphoma;    Biomarker discovery;   

Others  :  820228
DOI  :  10.1186/1477-5956-9-63

 received in 2011-05-13, accepted in 2011-10-05,  发布年份 2011

【 摘 要 】

Hodgkin lymphoma (HL) represents a category of lymphoid neoplasms with unique features, notably the usual scarcity of tumour cells in involved tissues. The most common subtype of classical HL, nodular sclerosis HL, characteristically comprises abundant fibrous tissue stroma. Little information is available about the protein composition of the stromal environment from HL. Moreover, the identification of valid protein targets, specifically and abundantly expressed in HL, would be of utmost importance for targeted therapies and imaging, yet the biomarkers must necessarily be accessible from the bloodstream. To characterize HL stroma and to identify potentially accessible proteins, we used a chemical proteomic approach, consisting in the labelling of accessible proteins and their subsequent purification and identification by mass spectrometry. We performed an analysis of potentially accessible proteins in lymph node biopsies from HL and reactive lymphoid tissues, and in total, more than 1400 proteins were identified in 7 samples. We have identified several extracellular matrix proteins overexpressed in HL, such as versican, fibulin-1, periostin, and other proteins such as S100-A8. These proteins were validated by immunohistochemistry on a larger series of biopsy samples, and bear the potential to become targets for antibody-based anti-cancer therapies.

【 授权许可】

   
2011 Kischel et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Swerdlow SH, Campo E, Harris N, Jaffe E, Pileri S, Stein H, Thiele J, Vardiman JW: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon: WHO; 2008.
• [2]Khan G: Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp Hematol 2006, 34:399-406.
• [3]Liotta LA, Kohn EC: The microenvironment of the tumour-host interface. Nature 2001, 411:375-379.
• [4]Thorns C, Gaiser T, Lange K, Merz H, Feller AC: cDNA arrays: gene expression profiles of Hodgkin's disease and anaplastic large cell lymphoma cell lines. Pathol Int 2002, 52:578-585.
• [5]Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG: Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002, 1:304-313.
• [6]Anderson L, Seilhamer J: A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997, 18:533-537.
• [7]Cussac D, Pichereaux C, Colomba A, Capilla F, Pont F, Gaits-Iacovoni F, Lamant L, Espinos E, Burlet-Schiltz O, Monsarrat B, et al.: Proteomic analysis of anaplastic lymphoma cell lines: identification of potential tumour markers. Proteomics 2006, 6:3210-3222.
• [8]Ma Y, Visser L, Roelofsen H, de Vries M, Diepstra A, van Imhoff G, van der Wal T, Luinge M, Alvarez-Llamas G, Vos H, et al.: Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood 2008, 111:2339-2346.
• [9]Wallentine JC, Kim KK, Seiler CE, Vaughn CP, Crockett DK, Tripp SR, Elenitoba-Johnson KS, Lim MS: Comprehensive identification of proteins in Hodgkin lymphoma-derived Reed-Sternberg cells by LC-MS/MS. Lab Invest 2007, 87:1113-1124.
• [10]Kamper P, Ludvigsen M, Bendix K, Hamilton-Dutoit S, Rabinovich GA, Møller MB, Nyengaard JR, Honoré B, d'Amore F: Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood 2011, 117:6638-6649.
• [11]Antonucci F, Chilosi M, Santacatterina M, Herbert B, Righetti PG: Proteomics and immunomapping of reactive lymph-node and lymphoma. Electrophoresis 2002, 23:356-362.
• [12]Antonucci F, Chilosi M, Parolini C, Hamdan M, Astner H, Righetti PG: Two-dimensional molecular profiling of mantle cell lymphoma. Electrophoresis 2003, 24:2376-2385.
• [13]Rolland D, Bouamrani A, Houlgatte R, Barbarat A, Ramus C, Arlotto M, Ballester B, Berger F, Felman P, Callet-Bauchu E, et al.: Identification of proteomic signatures of mantle cell lymphoma, small lymphocytic lymphoma, and marginal zone lymphoma biopsies by surface enhanced laser desorption/ionization-time of flight mass spectrometry. Leukemia & Lymphoma 2011, 52:648-658.
• [14]Li J, Okamoto H, Yin C, Jagannathan J, Takizawa J, Aoki S, Glasker S, Rushing EJ, Vortmeyer AO, Oldfield EH, et al.: Proteomic characterization of primary diffuse large B-cell lymphomas in the central nervous system. J Neurosurg 2008, 109:536-546.
• [15]Castronovo V, Kischel P, Guillonneau F, de Leval L, Defechereux T, De Pauw E, Neri D, Waltregny D: Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method. Proteomics 2007, 7:1188-1196.
• [16]Liu H, Sadygov RG, Yates JR: A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004, 76:4193-4201.
• [17]Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, Raymond WA, Seshadri R, LeBaron RG, Horsfall DJ: Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 2002, 8:1054-1060.
• [18]Argraves WS, Greene LM, Cooley MA, Gallagher WM: Fibulins: physiological and disease perspectives. EMBO Rep 2003, 4:1127-1131.
• [19]Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD: Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res 2002, 62:5358-5364.
• [20]Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, Angel P, Mayer D: Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 2005, 11:5146-5152.
• [21]Neri D, Bicknell R: Tumour vascular targeting. Nat Rev Cancer 2005, 5:436-446.
• [22]De Wever O, Mareel M: Role of tissue stroma in cancer cell invasion. J Pathol 2003, 200:429-447.
• [23]Zardi L, Neri D: Affinity reagents against tumour-associated extracellular molecules and newforming vessels. Adv Drug Deliv Rev 1998, 31:43-52.
• [24]Albini A, Sporn MB: The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007, 7:139-147.
• [25]Adams GP, Weiner LM: Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23:1147-1157.
• [26]Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganelli G, Mariani G, et al.: Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009, 113:2265-2274.
• [27]Durr E, Yu J, Krasinska KM, Carver LA, Yates JR, Testa JE, Oh P, Schnitzer JE: Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat Biotechnol 2004, 22:985-992.
• [28]Rybak JN, Ettorre A, Kaissling B, Giavazzi R, Neri D, Elia G: In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods 2005, 2:291-298.
• [29]Lazar P, Brezin C, Oudin J: [Classification of 29 Hodgkin's disease patients as a function of the concentration of 22 serum antigens]. Ann Biol Clin (Paris) 1975, 33:35-40.
• [30]Samoszuk MK, Anderson AL, Ramzi E, Wang F, Braunstein P, Lutsky J, Majmundar H, Slater LM: Radioimmunodetection of Hodgkin's Disease and Non-Hodgkin's Lymphomas with Monoclonal Antibody to Eosinophil Peroxidase. Journal of Nuclear Medicine 1993, 34:1246-1253.
• [31]Adany R, Szegedi A, Ablin RJ, Muszbek L: Fibrinolysis resistant fibrin deposits in lymph nodes with Hodgkin's disease. Thrombosis and haemostasis 1988, 60:293-297.
• [32]Niitsu N, Nakamine H, Okamoto M, Tamaru Ji, Hirano M: A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma. Annals of Oncology 2008, 19:1941-1946.
• [33]Roger P, Pujol P, Lucas A, Baldet P, Rochefort H: Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors. Am J Pathol 1998, 153:1579-1588.
• [34]Bensadoun ES, Burke AK, Hogg JC, Roberts CR: Proteoglycan deposition in pulmonary fibrosis. Am J Respir Crit Care Med 1996, 154:1819-1828.
• [35]Piscaglia F, Dudas J, Knittel T, Di Rocco P, Kobold D, Saile B, Zocco MA, Timpl R, Ramadori G: Expression of ECM proteins fibulin-1 and -2 in acute and chronic liver disease and in cultured rat liver cells. Cell Tissue Res 2009, 337:449-462.
• [36]Oka T, Xu J, Kaiser RA, Melendez J, Hambleton M, Sargent MA, Lorts A, Brunskill EW, Dorn GW, Conway SJ, et al.: Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res 2007, 101:313-321.
• [37]Waltregny D, Bellahcene A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewe W, de Leval J, Castronovo V: Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 1998, 90:1000-1008.